Deciphering and Reversing Tumor Immune Suppression

Immunity

Volumn 39, Issue 1, 2013, Pages 61-73

  Motz, GregT ^a   Coukos, George ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

ANTIGEN-PRESENTING CELLS; HUMANS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MYELOID CELLS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, REGULATORY;

EID: 84880757177     PISSN: 10747613     EISSN: 10974180     Source Type: Journal    
DOI: 10.1016/j.immuni.2013.07.005     Document Type: Review

References (181)

1. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105:1815-1822.
2. Almand B., Resser J.R., Lindman B., Nadaf S., Clark J.I., Kwon E.D., Carbone D.P., Gabrilovich D.I. Clinical significance of defective dendritic cell differentiation in cancer. Clin. Cancer Res. 2000, 6:1755-1766.
3. Bagnato A., Rosanò L. The endothelin axis in cancer. Int. J. Biochem. Cell Biol. 2008, 40:1443-1451.
4. Bagnato A., Salani D., Di Castro V., Wu-Wong J.R., Tecce R., Nicotra M.R., Venuti A., Natali P.G. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 1999, 59:720-727.
5. Balkwill F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9:361-371.
6. Batista C.E., Juhász C., Muzik O., Kupsky W.J., Barger G., Chugani H.T., Mittal S., Sood S., Chakraborty P.K., Chugani D.C. Imaging correlates of differential expression of indoleamine 2,3-dioxygenase in human brain tumors. Mol. Imaging Biol. 2009, 11:460-466.
7. Ben-Shoshan J., Maysel-Auslender S., Mor A., Keren G., George J. Hypoxia controls CD4+CD25+ regulatory T-cell homeostasis via hypoxia-inducible factor-1alpha. Eur. J. Immunol. 2008, 38:2412-2418.
8. Blaschitz A., Gauster M., Fuchs D., Lang I., Maschke P., Ulrich D., Karpf E., Takikawa O., Schimek M.G., Dohr G., Sedlmayr P. Vascular endothelial expression of indoleamine 2,3-dioxygenase 1 forms a positive gradient towards the feto-maternal interface. PLoS ONE 2011, 6:e21774.
9. Boissonnas A., Fetler L., Zeelenberg I.S., Hugues S., Amigorena S. Invivo imaging of cytotoxic Tcell infiltration and elimination of a solid tumor. J.Exp. Med. 2007, 204:345-356.
10. Bonertz A., Weitz J., Pietsch D.H., Rahbari N.N., Schlude C., Ge Y., Juenger S., Vlodavsky I., Khazaie K., Jaeger D., et al. Antigen-specific Tregs control Tcell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J.Clin. Invest. 2009, 119:3311-3321.
11. Boon T., Coulie P.G., Van den Eynde B.J., van der Bruggen P. Human Tcell responses against melanoma. Annu. Rev. Immunol. 2006, 24:175-208.
12. Bouzin C., Brouet A., De Vriese J., Dewever J., Feron O. Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy. J.Immunol. 2007, 178:1505-1511.
13. Brahmer J.R., Tykodi S.S., Chow L.Q., Hwu W.J., Topalian S.L., Hwu P., Drake C.G., Camacho L.H., Kauh J., Odunsi K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N.Engl. J. Med. 2012, 366:2455-2465.
14. Braun D., Longman R.S., Albert M.L. A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation. Blood 2005, 106:2375-2381.
15. Bronte V., Apolloni E., Cabrelle A., Ronca R., Serafini P., Zamboni P., Restifo N.P., Zanovello P. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) Tcells. Blood 2000, 96:3838-3846.
16. Bronte V., Kasic T., Gri G., Gallana K., Borsellino G., Marigo I., Battistini L., Iafrate M., Prayer-Galetti T., Pagano F., Viola A. Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers. J.Exp. Med. 2005, 201:1257-1268.
17. Brown C.E., Vishwanath R.P., Aguilar B., Starr R., Najbauer J., Aboody K.S., Jensen M.C. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred Tcells. J.Immunol. 2007, 179:3332-3341.
18. Buckanovich R.J., Facciabene A., Kim S., Benencia F., Sasaroli D., Balint K., Katsaros D., O'Brien-Jenkins A., Gimotty P.A., Coukos G. Endothelin B receptor mediates the endothelial barrier to Tcell homing to tumors and disables immune therapy. Nat. Med. 2008, 14:28-36.
19. Carosella E.D., Moreau P., Le Maoult J., Le Discorde M., Dausset J., Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003, 81:199-252.
20. Castle J.C., Kreiter S., Diekmann J., Löwer M., van de Roemer N., de Graaf J., Selmi A., Diken M., Boegel S., Paret C., et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 2012, 72:1081-1091.
21. Cavassani K.A., Ishii M., Wen H., Schaller M.A., Lincoln P.M., Lukacs N.W., Hogaboam C.M., Kunkel S.L. TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J.Exp. Med. 2008, 205:2609-2621.
22. Chambers C.A., Kuhns M.S., Egen J.G., Allison J.P. CTLA-4-mediated inhibition in regulation of Tcell responses: mechanisms and manipulation in tumor immunotherapy. Annu. Rev. Immunol. 2001, 19:565-594.
23. Chang C.C., Campoli M., Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: current challenges and future directions. Adv. Cancer Res. 2005, 93:189-234.
24. Chen W., Jin W., Hardegen N., Lei K.J., Li L., Marinos N., McGrady G., Wahl S.M. Conversion of peripheral CD4+CD25- naive Tcells to CD4+CD25+ regulatory Tcells by TGF-beta induction of transcription factor Foxp3. J.Exp. Med. 2003, 198:1875-1886.
25. Coffelt S.B., Chen Y.Y., Muthana M., Welford A.F., Tal A.O., Scholz A., Plate K.H., Reiss Y., Murdoch C., De Palma M., Lewis C.E. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress Tcell activation and to promote regulatory Tcell expansion. J.Immunol. 2011, 186:4183-4190.
26. Conejo-Garcia J.R., Benencia F., Courreges M.C., Kang E., Mohamed-Hadley A., Buckanovich R.J., Holtz D.O., Jenkins A., Na H., Zhang L., et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat. Med. 2004, 10:950-958.
27. Curiel T.J., Wei S., Dong H., Alvarez X., Cheng P., Mottram P., Krzysiek R., Knutson K.L., Daniel B., Zimmermann M.C., et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat. Med. 2003, 9:562-567.
28. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., Evdemon-Hogan M., Conejo-Garcia J.R., Zhang L., Burow M., et al. Specific recruitment of regulatory Tcells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10:942-949.
29. Curotto de Lafaille M.A., Lafaille J.J. Natural and adaptive foxp3+ regulatory Tcells: more of the same or a division of labor?. Immunity 2009, 30:626-635.
30. Davenpeck K.L., Gauthier T.W., Lefer A.M. Inhibition of endothelial-derived nitric oxide promotes P-selectin expression and actions in the rat microcirculation. Gastroenterology 1994, 107:1050-1058.
31. De Caterina R., Libby P., Peng H.B., Thannickal V.J., Rajavashisth T.B., Gimbrone M.A., Shin W.S., Liao J.K. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J.Clin. Invest. 1995, 96:60-68.
32. de Chaisemartin L., Goc J., Damotte D., Validire P., Magdeleinat P., Alifano M., Cremer I., Fridman W.H., Sautès-Fridman C., Dieu-Nosjean M.C. Characterization of chemokines and adhesion molecules associated with Tcell presence in tertiary lymphoid structures in human lung cancer. Cancer Res. 2011, 71:6391-6399.
33. Deaglio S., Dwyer K.M., Gao W., Friedman D., Usheva A., Erat A., Chen J.F., Enjyoji K., Linden J., Oukka M., et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory Tcells mediates immune suppression. J.Exp. Med. 2007, 204:1257-1265.
34. Della Porta M., Danova M., Rigolin G.M., Brugnatelli S., Rovati B., Tronconi C., Fraulini C., Russo Rossi A., Riccardi A., Castoldi G. Dendritic cells and vascular endothelial growth factor in colorectal cancer: correlations with clinicobiological findings. Oncology 2005, 68:276-284.
35. Detmar M., Brown L.F., Schön M.P., Elicker B.M., Velasco P., Richard L., Fukumura D., Monsky W., Claffey K.P., Jain R.K. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J.Invest. Dermatol. 1998, 111:1-6.
36. Dirkx A.E., Oude Egbrink M.G., Kuijpers M.J., van der Niet S.T., Heijnen V.V., Bouma-ter Steege J.C., Wagstaff J., Griffioen A.W. Tumor angiogenesis modulates leukocyte-vessel wall interactions invivo by reducing endothelial adhesion molecule expression. Cancer Res. 2003, 63:2322-2329.
37. Dolfi D.V., Duttagupta P.A., Boesteanu A.C., Mueller Y.M., Oliai C.H., Borowski A.B., Katsikis P.D. Dendritic cells and CD28 costimulation are required to sustain virus-specific CD8+ Tcell responses during the effector phase invivo. J.Immunol. 2011, 186:4599-4608.
38. Dong H., Strome S.E., Salomao D.R., Tamura H., Hirano F., Flies D.B., Roche P.C., Lu J., Zhu G., Tamada K., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 2002, 8:793-800.
39. Dranoff G., Fearon D. Tumour immunology. Curr. Opin. Immunol. 2013, 25:189-191.
40. Du R., Lu K.V., Petritsch C., Liu P., Ganss R., Passegué E., Song H., Vandenberg S., Johnson R.S., Werb Z., Bergers G. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
41. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., Topalian S.L., Sherry R., Restifo N.P., Hubicki A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
42. Duraiswamy J., Kaluza K.M., Freeman G.J., Coukos G. Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors. Cancer Res. 2013, 73:3591-3603.
43. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011, 8:210-221.
44. Egen J.G., Kuhns M.S., Allison J.P. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002, 3:611-618.
45. Elia A.R., Cappello P., Puppo M., Fraone T., Vanni C., Eva A., Musso T., Novelli F., Varesio L., Giovarelli M. Human dendritic cells differentiated in hypoxia down-modulate antigen uptake and change their chemokine expression profile. J.Leukoc. Biol. 2008, 84:1472-1482.
46. Engels B., Rowley D.A., Schreiber H. Targeting stroma to treat cancers. Semin. Cancer Biol. 2012, 22:41-49.
47. Facciabene A., Peng X., Hagemann I.S., Balint K., Barchetti A., Wang L.P., Gimotty P.A., Gilks C.B., Lal P., Zhang L., Coukos G. Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells. Nature 2011, 475:226-230.
48. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res. 2012, 72:2162-2171.
49. Fontenot J.D., Rasmussen J.P., Gavin M.A., Rudensky A.Y. A function for interleukin 2 in Foxp3-expressing regulatory Tcells. Nat. Immunol. 2005, 6:1142-1151.
50. Frebel H., Nindl V., Schuepbach R.A., Braunschweiler T., Richter K., Vogel J., Wagner C.A., Loffing-Cueni D., Kurrer M., Ludewig B., Oxenius A. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J.Exp. Med. 2012, 209:2485-2499.
51. Fricke I., Mirza N., Dupont J., Lockhart C., Jackson A., Lee J.H., Sosman J.A., Gabrilovich D.I. Vascular endothelial growth factor-trap overcomes defects in dendritic cell differentiation but does not improve antigen-specific immune responses. Clin. Cancer Res. 2007, 13:4840-4848.
52. Frommer K.W., Müller-Ladner U. Expression and function of ETA and ETB receptors in SSc. Rheumatology (Oxford) 2008, 47(Suppl 5):v27-v28.
53. Fu H., Khan A., Coe D., Zaher S., Chai J.G., Kropf P., Müller I., Larkin D.F., George A.J. Arginine depletion as a mechanism for the immune privilege of corneal allografts. Eur. J. Immunol. 2011, 41:2997-3005.
54. Fukumura D., Yuan F., Endo M., Jain R.K. Role of nitric oxide in tumor microcirculation. Blood flow, vascular permeability, and leukocyte-endothelial interactions. Am. J. Pathol. 1997, 150:713-725.
55. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6:521-534.
56. Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat. Rev. Immunol. 2004, 4:941-952.
57. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
58. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., Kavanaugh D., Carbone D.P. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
59. Gabrilovich D.I., Ishida T., Nadaf S., Ohm J.E., Carbone D.P. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin. Cancer Res. 1999, 5:2963-2970.
60. Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012, 12:253-268.
61. Gallina G., Dolcetti L., Serafini P., De Santo C., Marigo I., Colombo M.P., Basso G., Brombacher F., Borrello I., Zanovello P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ Tcells. J.Clin. Invest. 2006, 116:2777-2790.
62. Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pagès C., Tosolini M., Camus M., Berger A., Wind P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006, 313:1960-1964.
63. Geissmann F., Revy P., Regnault A., Lepelletier Y., Dy M., Brousse N., Amigorena S., Hermine O., Durandy A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J.Immunol. 1999, 162:4567-4575.
64. Ghiringhelli F., Puig P.E., Roux S., Parcellier A., Schmitt E., Solary E., Kroemer G., Martin F., Chauffert B., Zitvogel L. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory Tcell proliferation. J.Exp. Med. 2005, 202:919-929.
65. Gondek D.C., Lu L.F., Quezada S.A., Sakaguchi S., Noelle R.J. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J.Immunol. 2005, 174:1783-1786.
66. Gottfried E., Kunz-Schughart L.A., Ebner S., Mueller-Klieser W., Hoves S., Andreesen R., Mackensen A., Kreutz M. Tumor-derived lactic acid modulates dendritic cell activation and antigen expression. Blood 2006, 107:2013-2021.
67. Griffioen A.W., Damen C.A., Blijham G.H., Groenewegen G. Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 1996, 88:667-673.
68. Griffioen A.W., Damen C.A., Martinotti S., Blijham G.H., Groenewegen G. Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res. 1996, 56:1111-1117.
69. Hamanishi J., Mandai M., Iwasaki M., Okazaki T., Tanaka Y., Yamaguchi K., Higuchi T., Yagi H., Takakura K., Minato N., et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007, 104:3360-3365.
70. Harlin H., Meng Y., Peterson A.C., Zha Y., Tretiakova M., Slingluff C., McKee M., Gajewski T.F. Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 2009, 69:3077-3085.
71. Hashimoto D., Miller J., Merad M. Dendritic cell and macrophage heterogeneity invivo. Immunity 2011, 35:323-335.
72. Hernández G.L., Volpert O.V., Iñiguez M.A., Lorenzo E., Martínez-Martínez S., Grau R., Fresno M., Redondo J.M. Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A: roles of the nuclear factor of activated Tcells and cyclooxygenase 2. J.Exp. Med. 2001, 193:607-620.
73. Hirano F., Kaneko K., Tamura H., Dong H., Wang S., Ichikawa M., Rietz C., Flies D.B., Lau J.S., Zhu G., et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 2005, 65:1089-1096.
74. Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N.Engl. J. Med. 2010, 363:711-723.
75. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
76. Huang X., Bai X., Cao Y., Wu J., Huang M., Tang D., Tao S., Zhu T., Liu Y., Yang Y., et al. Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion. J.Exp. Med. 2010, 207:505-520.
77. Huarte E., Cubillos-Ruiz J.R., Nesbeth Y.C., Scarlett U.K., Martinez D.G., Buckanovich R.J., Benencia F., Stan R.V., Keler T., Sarobe P., et al. Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res. 2008, 68:7684-7691.
78. Hwang W.T., Adams S.F., Tahirovic E., Hagemann I.S., Coukos G. Prognostic significance of tumor-infiltrating Tcells in ovarian cancer: a meta-analysis. Gynecol. Oncol. 2012, 124:192-198.
79. Ibberson M., Bron S., Guex N., Faes-Van't Hull E., Henry L., Ifticene-Treboux A., Lehr H.A., Delaloye J.F., Coukos G., Xenarios I., et al. TIE-2 and VEGFR kinase activities drive TIE-2-expressing monocytes immunosuppressive function in human breast tumors. Clin Cancer Res. 2013.
80. Ishida T., Oyama T., Carbone D.P., Gabrilovich D.I. Defective function of Langerhans cells in tumor-bearing animals is the result of defective maturation from hemopoietic progenitors. J.Immunol. 1998, 161:4842-4851.
81. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H., Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory Tcells in Hodgkin lymphoma fosters immune privilege. Cancer Res. 2006, 66:5716-5722.
82. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. USA 2002, 99:12293-12297.
83. Kaliński P., Hilkens C.M., Snijders A., Snijdewint F.G., Kapsenberg M.L. IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J.Immunol. 1997, 159:28-35.
84. Kammertoens T., Schüler T., Blankenstein T. Immunotherapy: target the stroma to hit the tumor. Trends Mol. Med. 2005, 11:225-231.
85. Kandalaft L.E., Motz G.T., Duraiswamy J., Coukos G. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance. Cancer Metastasis Rev. 2011, 30:141-151.
86. Kato T., Kameoka S., Kimura T., Soga N., Abe Y., Nishikawa T., Kobayashi M. Angiogenesis as a predictor of long-term survival for 377 Japanese patients with breast cancer. Breast Cancer Res. Treat. 2001, 70:65-74.
87. Kerkar S.P., Goldszmid R.S., Muranski P., Chinnasamy D., Yu Z., Reger R.N., Leonardi A.J., Morgan R.A., Wang E., Marincola F.M., et al. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J.Clin. Invest. 2011, 121:4746-4757.
88. Kim R., Emi M., Tanabe K., Arihiro K. Potential functional role of plasmacytoid dendritic cells in cancer immunity. Immunology 2007, 121:149-157.
89. Kontermann R. Dual targeting strategies with bispecific antibodies. mAbs 2012, 4:182-197.
90. Kryczek I., Zou L., Rodriguez P., Zhu G., Wei S., Mottram P., Brumlik M., Cheng P., Curiel T., Myers L., et al. B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J.Exp. Med. 2006, 203:871-881.
91. Kubes P., Suzuki M., Granger D.N. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 1991, 88:4651-4655.
92. Kwon E.D., Foster B.A., Hurwitz A.A., Madias C., Allison J.P., Greenberg N.M., Burg M.B. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc. Natl. Acad. Sci. USA 1999, 96:15074-15079.
93. Labidi-Galy S.I., Sisirak V., Meeus P., Gobert M., Treilleux I., Bajard A., Combes J.D., Faget J., Mithieux F., Cassignol A., et al. Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. Cancer Res. 2011, 71:5423-5434.
94. LeCouter J., Zlot C., Tejada M., Peale F., Ferrara N. Bv8 and endocrine gland-derived vascular endothelial growth factor stimulate hematopoiesis and hematopoietic cell mobilization. Proc. Natl. Acad. Sci. USA 2004, 101:16813-16818.
95. Lefer D.J., Jones S.P., Girod W.G., Baines A., Grisham M.B., Cockrell A.S., Huang P.L., Scalia R. Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice. Am. J. Physiol. 1999, 276:H1943-H1950.
96. Lin R., LeCouter J., Kowalski J., Ferrara N. Characterization of endocrine gland-derived vascular endothelial growth factor signaling in adrenal cortex capillary endothelial cells. J.Biol. Chem. 2002, 277:8724-8729.
97. Liu V.C., Wong L.Y., Jang T., Shah A.H., Park I., Yang X., Zhang Q., Lonning S., Teicher B.A., Lee C. Tumor evasion of the immune system by converting CD4+CD25- Tcells into CD4+CD25+ T regulatory cells: role of tumor-derived TGF-beta. J.Immunol. 2007, 178:2883-2892.
98. Loos T., Mortier A., Proost P. Chapter 1. Isolation, identification, and production of posttranslationally modified chemokines. Methods Enzymol. 2009, 461:3-29.
99. Loser K., Apelt J., Voskort M., Mohaupt M., Balkow S., Schwarz T., Grabbe S., Beissert S. IL-10 controls ultraviolet-induced carcinogenesis in mice. J.Immunol. 2007, 179:365-371.
100. Lukacs-Kornek V., Malhotra D., Fletcher A.L., Acton S.E., Elpek K.G., Tayalia P., Collier A.R., Turley S.J. Regulated release of nitric oxide by nonhematopoietic stroma controls expansion of the activated Tcell pool in lymph nodes. Nat. Immunol. 2011, 12:1096-1104.
101. Lurquin C., Lethé B., De Plaen E., Corbière V., Théate I., van Baren N., Coulie P.G., Boon T. Contrasting frequencies of antitumor and anti-vaccine Tcells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J.Exp. Med. 2005, 201:249-257.
102. Lutz M.B., Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?. Trends Immunol. 2002, 23:445-449.
103. Ma L., Mauro C., Cornish G.H., Chai J.G., Coe D., Fu H., Patton D., Okkenhaug K., Franzoso G., Dyson J., et al. Ig gene-like molecule CD31 plays a nonredundant role in the regulation of T-cell immunity and tolerance. Proc. Natl. Acad. Sci. USA 2010, 107:19461-19466.
104. Ma C., Zhang Q., Ye J., Wang F., Zhang Y., Wevers E., Schwartz T., Hunborg P., Varvares M.A., Hoft D.F., et al. Tumor-infiltrating γδ T lymphocytes predict clinical outcome in human breast cancer. J.Immunol. 2012, 189:5029-5036.
105. Magner W.J., Kazim A.L., Stewart C., Romano M.A., Catalano G., Grande C., Keiser N., Santaniello F., Tomasi T.B. Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors. J.Immunol. 2000, 165:7017-7024.
106. Mahnke K., Schmitt E., Bonifaz L., Enk A.H., Jonuleit H. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol. Cell Biol. 2002, 80:477-483.
107. Manning E.A., Ullman J.G., Leatherman J.M., Asquith J.M., Hansen T.R., Armstrong T.D., Hicklin D.J., Jaffee E.M., Emens L.A. A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. Clin. Cancer Res. 2007, 13:3951-3959.
108. Marincola F.M., Jaffee E.M., Hicklin D.J., Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol. 2000, 74:181-273.
109. Martin-Orozco N., Muranski P., Chung Y., Yang X.O., Yamazaki T., Lu S., Hwu P., Restifo N.P., Overwijk W.W., Dong C. T helper 17 cells promote cytotoxic Tcell activation in tumor immunity. Immunity 2009, 31:787-798.
110. Mazanet M.M., Hughes C.C. B7-H1 is expressed by human endothelial cells and suppresses Tcell cytokine synthesis. J.Immunol. 2002, 169:3581-3588.
111. Meidan R., Levy N. The ovarian endothelin network: an evolving story. Trends Endocrinol. Metab. 2007, 18:379-385.
112. Mellman I., Steinman R.M. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001, 106:255-258.
113. Mendler A.N., Hu B., Prinz P.U., Kreutz M., Gottfried E., Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int. J. Cancer 2012, 131:633-640.
114. Menetrier-Caux C., Montmain G., Dieu M.C., Bain C., Favrot M.C., Caux C., Blay J.Y. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998, 92:4778-4791.
115. Min J.K., Lee Y.M., Kim J.H., Kim Y.M., Kim S.W., Lee S.Y., Gho Y.S., Oh G.T., Kwon Y.G. Hepatocyte growth factor suppresses vascular endothelial growth factor-induced expression of endothelial ICAM-1 and VCAM-1 by inhibiting the nuclear factor-kappaB pathway. Circ. Res. 2005, 96:300-307.
116. Molon B., Ugel S., Del Pozzo F., Soldani C., Zilio S., Avella D., De Palma A., Mauri P., Monegal A., Rescigno M., et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific Tcells. J.Exp. Med. 2011, 208:1949-1962.
117. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
118. Mulligan J.K., Young M.R. Tumors induce the formation of suppressor endothelial cells invivo. Cancer Immunol. Immunother 2010, 59:267-277.
119. Mulligan J.K., Day T.A., Gillespie M.B., Rosenzweig S.A., Young M.R. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Hum. Immunol. 2009, 70:375-382.
120. Munn D.H., Mellor A.L. IDO and tolerance to tumors. Trends Mol. Med. 2004, 10:15-18.
121. Murdoch C., Muthana M., Coffelt S.B., Lewis C.E. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
122. Muthuswamy R., Mueller-Berghaus J., Haberkorn U., Reinhart T.A., Schadendorf D., Kalinski P. PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive Tcells. Blood 2010, 116:1454-1459.
123. Muthuswamy R., Berk E., Junecko B.F., Zeh H.J., Zureikat A.H., Normolle D., Luong T.M., Reinhart T.A., Bartlett D.L., Kalinski P. NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res. 2012, 72:3735-3743.
124. Nair S., Boczkowski D., Moeller B., Dewhirst M., Vieweg J., Gilboa E. Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 2003, 102:964-971.
125. Naito Y., Saito K., Shiiba K., Ohuchi A., Saigenji K., Nagura H., Ohtani H. CD8+ Tcells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res. 1998, 58:3491-3494.
126. Neller M.A., López J.A., Schmidt C.W. Antigens for cancer immunotherapy. Semin. Immunol. 2008, 20:286-295.
127. Nelson J., Bagnato A., Battistini B., Nisen P. The endothelin axis: emerging role in cancer. Nat. Rev. Cancer 2003, 3:110-116.
128. Network C.G.A. Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70. Cancer Genome Atlas Network.
129. Osada T., Chong G., Tansik R., Hong T., Spector N., Kumar R., Hurwitz H.I., Dev I., Nixon A.B., Lyerly H.K., et al. The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol. Immunother. 2008, 57:1115-1124.
130. Palazón A., Aragonés J., Morales-Kastresana A., de Landázuri M.O., Melero I. Molecular pathways: hypoxia response in immune cells fighting or promoting cancer. Clin. Cancer Res. 2012, 18:1207-1213.
131. Pandiyan P., Zheng L., Ishihara S., Reed J., Lenardo M.J. CD4+CD25+Foxp3+ regulatory Tcells induce cytokine deprivation-mediated apoptosis of effector CD4+ Tcells. Nat. Immunol. 2007, 8:1353-1362.
132. Piersma S.J., Jordanova E.S., van Poelgeest M.I., Kwappenberg K.M., van der Hulst J.M., Drijfhout J.W., Melief C.J., Kenter G.G., Fleuren G.J., Offringa R., van der Burg S.H. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 2007, 67:354-361.
133. Pirtskhalaishvili G., Nelson J.B. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000, 44:77-87.
134. Pivarcsi A., Müller A., Hippe A., Rieker J., van Lierop A., Steinhoff M., Seeliger S., Kubitza R., Pippirs U., Meller S., et al. Tumor immune escape by the loss of homeostatic chemokine expression. Proc. Natl. Acad. Sci. USA 2007, 104:19055-19060.
135. Proost P., Mortier A., Loos T., Vandercappellen J., Gouwy M., Ronsse I., Schutyser E., Put W., Parmentier M., Struyf S., Van Damme J. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007, 110:37-44.
136. Propper D.J., Chao D., Braybrooke J.P., Bahl P., Thavasu P., Balkwill F., Turley H., Dobbs N., Gatter K., Talbot D.C., et al. Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma. Clin. Cancer Res. 2003, 9:84-92.
137. Ren X., Ye F., Jiang Z., Chu Y., Xiong S., Wang Y. Involvement of cellular death in TRAIL/DR5-dependent suppression induced by CD4(+)CD25(+) regulatory Tcells. Cell Death Differ. 2007, 14:2076-2084.
138. Riesenberg R., Weiler C., Spring O., Eder M., Buchner A., Popp T., Castro M., Kammerer R., Takikawa O., Hatz R.A., et al. Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma. Clin. Cancer Res. 2007, 13:6993-7002.
139. Riley J.L. PD-1 signaling in primary Tcells. Immunol. Rev. 2009, 229:114-125.
140. Robbins P.F., Lu Y.C., El-Gamil M., Li Y.F., Gross C., Gartner J., Lin J.C., Teer J.K., Cliften P., Tycksen E., et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive Tcells. Nat. Med. 2013, 19:747-752.
141. Robert C., Thomas L., Bondarenko I., O'Day S., M D J.W., Garbe C., Lebbe C., Baurain J.F., Testori A., Grob J.J., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N.Engl. J. Med. 2011, 364:2517-2526.
142. Rodgers J.R., Cook R.G. MHC class Ib molecules bridge innate and acquired immunity. Nat. Rev. Immunol. 2005, 5:459-471.
143. Rodig N., Ryan T., Allen J.A., Pang H., Grabie N., Chernova T., Greenfield E.A., Liang S.C., Sharpe A.H., Lichtman A.H., Freeman G.J. Endothelial expression of PD-L1 and PD-L2 down-regulates CD8+ Tcell activation and cytolysis. Eur. J. Immunol. 2003, 33:3117-3126.
144. Roland C.L., Lynn K.D., Toombs J.E., Dineen S.P., Udugamasooriya D.G., Brekken R.A. Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer. PLoS ONE 2009, 4:e7669.
145. Rosanò L., Spinella F., Salani D., Di Castro V., Venuti A., Nicotra M.R., Natali P.G., Bagnato A. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma. Cancer Res. 2003, 63:2447-2453.
146. Saida K., Mitsui Y., Ishida N. A novel peptide, vasoactive intestinal contractor, of a new (endothelin) peptide family. Molecular cloning, expression, and biological activity. J.Biol. Chem. 1989, 264:14613-14616.
147. Sainz-Perez A., Lim A., Lemercier B., Leclerc C. The T-cell receptor repertoire of tumor-infiltrating regulatory T lymphocytes is skewed toward public sequences. Cancer Res. 2012, 72:3557-3569.
148. Salani D., Taraboletti G., Rosanò L., Di Castro V., Borsotti P., Giavazzi R., Bagnato A. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization invivo. Am. J. Pathol. 2000, 157:1703-1711.
149. Sata M., Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 1998, 4:415-420.
150. Sawant A., Hensel J.A., Chanda D., Harris B.A., Siegal G.P., Maheshwari A., Ponnazhagan S. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J.Immunol. 2012, 189:4258-4265.
151. Schlienger K., Chu C.S., Woo E.Y., Rivers P.M., Toll A.J., Hudson B., Maus M.V., Riley J.L., Choi Y., Coukos G., et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted Tcells specific for autologous tumor in late-stage ovarian cancer patients. Clin. Cancer Res. 2003, 9:1517-1527.
152. Secchiero P., Zauli G. The puzzling role of TRAIL in endothelial cell biology. Arterioscler. Thromb. Vasc. Biol. 2008, 28:e4. author reply e5-e6.
153. Segal N.H., Parsons D.W., Peggs K.S., Velculescu V., Kinzler K.W., Vogelstein B., Allison J.P. Epitope landscape in breast and colorectal cancer. Cancer Res. 2008, 68:889-892.
154. Selby M.J., Engelhardt J.J., Quigley M., Henning K.A., Chen T., Srinivasan M., Korman A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T Cells. Cancer Immunology Research 2013, Published online April 7, 2013. DOI: 1158/2326-6066.
155. Seo N., Hayakawa S., Takigawa M., Tokura Y. Interleukin-10 expressed at early tumour sites induces subsequent generation of CD4(+) T-regulatory cells and systemic collapse of antitumour immunity. Immunology 2001, 103:449-457.
156. Shojaei F., Wu X., Zhong C., Yu L., Liang X.H., Yao J., Blanchard D., Bais C., Peale F.V., van Bruggen N., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
157. Spinella F., Rosanò L., Di Castro V., Natali P.G., Bagnato A. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells. J.Biol. Chem. 2002, 277:27850-27855.
158. Spinella F., Rosanò L., Di Castro V., Decandia S., Nicotra M.R., Natali P.G., Bagnato A. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res. 2007, 67:1725-1734.
159. Steinbrink K., Jonuleit H., Müller G., Schuler G., Knop J., Enk A.H. Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) Tcells resulting in a failure to lyse tumor cells. Blood 1999, 93:1634-1642.
160. Steinman R.M., Turley S., Mellman I., Inaba K. The induction of tolerance by dendritic cells that have captured apoptotic cells. J.Exp. Med. 2000, 191:411-416.
161. Strauss L., Bergmann C., Szczepanski M., Gooding W., Johnson J.T., Whiteside T.L. A unique subset of CD4+CD25highFoxp3+ Tcells secreting interleukin-10 and transforming growth factor-beta1 mediates suppression in the tumor microenvironment. Clin. Cancer Res. 2007, 13:4345-4354.
162. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., Toes R.E., Offringa R., Melief C.J. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory Tcells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J.Exp. Med. 2001, 194:823-832.
163. Takahashi A., Kono K., Ichihara F., Sugai H., Fujii H., Matsumoto Y. Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide, but not by proinflammatory cytokines. Cancer Immunol. Immunother. 2004, 53:543-550.
164. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., Powderly J.D., Carvajal R.D., Sosman J.A., Atkins M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N.Engl. J. Med. 2012, 366:2443-2454.
165. Topp M.S., Kufer P., Gökbuget N., Goebeler M., Klinger M., Neumann S., Horst H.A., Raff T., Viardot A., Schmid M., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J.Clin. Oncol. 2011, 29:2493-2498.
166. Valzasina B., Piconese S., Guiducci C., Colombo M.P. Tumor-induced expansion of regulatory Tcells by conversion of CD4+CD25- lymphocytes is thymus and proliferation independent. Cancer Res. 2006, 66:4488-4495.
167. van Elsas A., Sutmuller R.P., Hurwitz A.A., Ziskin J., Villasenor J., Medema J.P., Overwijk W.W., Restifo N.P., Melief C.J., Offringa R., Allison J.P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J.Exp. Med. 2001, 194:481-489.
168. Vignali D.A., Collison L.W., Workman C.J. How regulatory Tcells work. Nat. Rev. Immunol. 2008, 8:523-532.
169. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
170. Watchmaker P.B., Berk E., Muthuswamy R., Mailliard R.B., Urban J.A., Kirkwood J.M., Kalinski P. Independent regulation of chemokine responsiveness and cytolytic function versus CD8+ Tcell expansion by dendritic cells. J.Immunol. 2010, 184:591-597.
171. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., Thompson C.B., Griesser H., Mak T.W. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995, 270:985-988.
172. Whiteside T.L. Tumor-induced death of immune cells: its mechanisms and consequences. Semin. Cancer Biol. 2002, 12:43-50.
173. Whiteside T.L. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin. Cancer Biol. 2006, 16:3-15.
174. Yanagisawa M., Masaki T. Molecular biology and biochemistry of the endothelins. Trends Pharmacol. Sci. 1989, 10:374-378.
175. Yang L., DeBusk L.M., Fukuda K., Fingleton B., Green-Jarvis B., Shyr Y., Matrisian L.M., Carbone D.P., Lin P.C. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
176. Zang X., Sullivan P.S., Soslow R.A., Waitz R., Reuter V.E., Wilton A., Thaler H.T., Arul M., Slovin S.F., Wei J., et al. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Mod. Pathol. 2010, 23:1104-1112.
177. Zarek P.E., Huang C.T., Lutz E.R., Kowalski J., Horton M.R., Linden J., Drake C.G., Powell J.D. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory Tcells. Blood 2008, 111:251-259.
178. Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Makrigiannakis A., Gray H., Schlienger K., Liebman M.N., et al. Intratumoral Tcells, recurrence, and survival in epithelial ovarian cancer. N.Engl. J. Med. 2003, 348:203-213.
179. Zitvogel L., Kroemer G. Anticancer immunochemotherapy using adjuvants with direct cytotoxic effects. J.Clin. Invest. 2009, 119:2127-2130.
180. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 2006, 6:715-727.
181. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 2005, 5:263-274.